Open AccessAfrican Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials
Author(s) -
Zhou Yan,
Elashoff David,
Kremen Sarah,
Teng Edmond,
Karlawish Jason,
Grill Joshua D.
Publication year - 2017
Publication title -
alzheimer's and dementia: translational research and clinical interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.49
H-Index - 30
ISSN - 2352-8737
DOI - 10.1016/j.trci.2016.09.004
Subject(s) - clinical trial , african american , disease , medicine , gerontology , placebo , race (biology) , incidence (geometry) , alternative medicine , family medicine , psychology , pathology , ethnology , botany , physics , biology , optics , history
Alzheimer's disease (AD) incidence is disproportionately high in African Americans, yet, recruitment of this community to AD clinical trials is challenging. Methods We compared 47 African Americans and 78 whites in their willingness to enroll in a hypothetical preclinical AD trial and examined barriers and facilitators in their decision making. Results African American race (OR = 0.45; 95% CI, 0.22–0.93) and score on the research attitude questionnaire (OR = 1.12; 95% CI, 1.04–1.22) were independently associated with willingness to participate. African Americans rated study risks, the requirement of a study partner, study procedures, the ratio of drug to placebo, and study location as more important factors in the decision whether to enroll than did whites. Discussion These results suggest that researchers will encounter challenges in recruiting African Americans to preclinical AD trials. Future research will be necessary to understand the optimal means to improve recruitment of underrepresented populations.